The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
Open accessAbstract
Accumulating evidence has implicated that GLP-1 may have a beneficial effect on cardiovascular and renal diseases but the mechanism is not fully understood. Here we show that GLP-1 analog, liraglutide, inhibits oxidative stress and albuminuria in streptozotocin (STZ)-induced type 1 diabetes mellitus rats, via a protein kinase A (PKA)-mediated inhibition of renal NAD(P)H oxidases. Diabetic rats were randomly treated with subcutaneous injections of liraglutide (0.3 mg/kg/12 h) for 4 weeks. Oxidative stress markers (urinary 8-hydroxy-2'-deoxyguanosine and renal dihydroethidium staining), expression of renal NAD(P)H oxidase components, transforming growth factor-β (TGF-β), fibronectin and urinary albumin excretion were measured. In vitro effect of liraglutide was evaluated using cultured renal mesangial cells. Administration of liraglutide did not affect plasma glucose levels or body weights in STZ diabetic rats, but normalized oxidative stress markers, expression of NAD(P)H oxidase components, TGF-β, fibronectin in renal tissues and urinary albumin excretion, all of which were significantly increased in diabetic rats. In addition, in cultured renal mesangial cells, incubation with liraglutide for 48 h inhibited NAD(P)H-dependent superoxide production evaluated by lucigenin chemiluminescence in a dose-dependent manner. This effect was reversed by both PKA inhibitor H89 and adenylate cyclase inhibitor SQ22536, but not by Epac2 inhibition via its small interfering RNA. Liraglutide may have a direct beneficial effect on oxidative stress and diabetic nephropathy via a PKA-mediated inhibition of renal NAD(P)H oxidase, independently of a glucose-lowering effect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Liraglutide inhibited NOX4 enzymatic activity, and this effect could be blocked by incubation with a protein kinase inhibitor or an adenylate cyclase inhibitor (62).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [62]
In the citing paper
“Indeed, early preclinical studies demonstrated attenuation of renal TGF-β expression in association with reduced expression of collagens within the kidney after GLP-1 receptor agonist therapy (62).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [62]
Citations
Cites
Role of Oxidative Stress in Development of Complications in Diabetes
Baynes, J. (1991) · Diabetes · doi:10.2337/diab.40.4.405 · Cited by 3,791
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Inoguchi, T., Li, P., Umeda, F., Yu, H. Y., Kakimoto, M., Imamura, M., Aoki, T., Etoh, T., Hashimoto, T., Naruse, M., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1939 · Cited by 1,577
Self-citationMechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus
Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., Skatchkov, M. P., Thaiss, F., Stahl, R. A. K., Warnholtz, A., et al. (2001) · Circulation Research · doi:10.1161/01.res.88.2.e14 · Cited by 1,191
Oberley, L. W. (1988) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(88)90036-6 · Cited by 1,105
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Identification of Renox, an NAD(P)H oxidase in kidney
Geiszt, M., Kopp, J. B., Várnai, P., & Leto, T. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130135897 · Cited by 840
Nox proteins in signal transduction
Brown, D., & Griendling, K. K. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.07.023 · Cited by 837
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 711
Cited by
Sorted by citations
Items 101–200 of 232
Neff, K., Elliott, J. A., Corteville, C., Abegg, K., Boza, C., Lutz, T. A., Docherty, N. G., & le Roux, C. W. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.08.026 · Cited by 30
Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Chen, J., Cooper, M., & Coughlan, M. T. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101641 · Cited by 32
Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension
Liu, L., Liu, J., & Huang, Y. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000176 · Cited by 28
Nephroprotective Properties of Antidiabetic Drugs
Gerdes, C., Muller, N., Wolf, G., & Busch, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103377 · Cited by 30
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 27
Yao, M., Jing, Z., Shu-qin, G., Xiao-liang, B., Zhi-hong, L., & Zhou, X. (2019) · Bioscience Reports · doi:10.1042/bsr20190109 · Cited by 28
Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Yip, J., Chiang, G. S. H., Lee, I. C. J., Lehming-Teo, R., Dai, K., Dongol, L., Wang, L. Y.-T., Teo, D. W. X., Seah, G. T., & Lehming, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010364 · Cited by 31
Jung, G., Jeon, J., Choe, M. S., Kim, S.-W., Lee, I., Kim, M.-K., & Park, K.-G. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.3.211 · Cited by 27
Liraglutide attenuates the migration of retinal pericytes induced by advanced glycation end products
Lin, W., Ma, X., Hao, M., Zhou, H., Yu, X., Shao, N., Gao, X., & Kuang, H. (2018) · Peptides · doi:10.1016/j.peptides.2018.05.003 · Cited by 27
Cappetta, D., Ciuffreda, L. P., Cozzolino, A., Esposito, G., Scavone, C., Sapio, L., Naviglio, S., D’Amario, D., Crea, F., Rossi, F., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8912768 · Cited by 26
Kuthati, Y., Davuluri, V. N. G., & Wong, C. (2025) · Biomolecules · doi:10.3390/biom15050622 · Cited by 30
A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease
Liu, C., Yang, M., Li, L., Luo, S., Yang, J., Li, C., Liu, J., & Sun, L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.909569 · Cited by 28
Terawaki, Y., Nomiyama, T., Takahashi, H., Tsutsumi, Y., Murase, K., Nagaishi, R., Tanabe, M., Kudo, T., Kobayashi, K., Yasuno, T., et al. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0043-2 · Cited by 25
Silva, V. D. O., Lobato, R. V., Andrade, E. F., Orlando, D. R., Borges, B. D. B., Zangerônimo, M. G., de Sousa, R., & Pereira, L. J. (2017) · Nutrients · doi:10.3390/nu9091016 · Cited by 25
el‐Rady, N. M. A., Ahmed, A., Abdel‐Rady, M. M., & Ismail, O. I. (2020) · Physiological Reports · doi:10.14814/phy2.14651 · Cited by 30
Rroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 28
Benefits of healthy adipose tissue in the treatment of diabetes
Gunawardana, S. C. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i4.420 · Cited by 26
Antioxidative Potentials of Incretin‐Based Medications: A Review of Molecular Mechanisms
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9959320 · Cited by 26
Boye, K. S., Botros, F. T., Haupt, A., Woodward, B., & Lage, M. J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0377-5 · Cited by 24
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 26
Ziebarth, J., da Silva, L. M., Lorenzett, A. K. P., Figueiredo, I. D., Carlstrom, P. F., Cardoso, F. N., de Freitas, A. L. F., Baviera, A. M., & Mainardes, R. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050634 · Cited by 23
Effects of Alogliptin in Chronic Kidney Disease Patients with Type 2 Diabetes
Sakai, Y., Suzuki, A., Mugishima, K., Sumi, Y., Otsuka, Y., Otsuka, T., Ohno, D., Murasawa, T., & Tsuruoka, S. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.1292 · Cited by 23
Hussien, N. I., Sorour, S. M., Elkerdasy, H., & Abdelrahman, B. A. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12944 · Cited by 21
Liljedahl, L., Pedersen, M. H., McGuire, J. N., & James, P. (2019) · Physiological Reports · doi:10.14814/phy2.13994 · Cited by 21
Next-generation therapeutics for diabetic kidney disease
Yi, T. W., Sridhar, V. S., Scott, J., Nardone, M., & Cherney, D. Z. I. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01042-0 · Cited by 24
Liraglutide Improves Renal Endothelial Function in Obese Zucker Rats on a High-Salt Diet
Sukumaran, V., Tsuchimochi, H., Sonobe, T., Shirai, M., & Pearson, J. T. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254821 · Cited by 21
Zhou, L., Dong, H., Huang, Y., Xu, L., Zou, X., Wang, K., Chen, G., & Lu, F. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/504642 · Cited by 21
Patschan, D., Schwarze, K., Lange, A., Meise, N., Henze, E., Becker, J. U., Patschan, S. A., & Muller, G. A. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00677.2012 · Cited by 21
Li, L.-Q., Yao, M.-Y., Ma, J.-X., Xue, P., & Li, Y.-K. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0016 · Cited by 20
“Liraglutide has been demonstrated to have antioxidative and anti-inflammatory effects [29, 30].”
BackgroundEffects of incretin-based therapies on renal function
Tsimihodimos, V., & Elisaf, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.049 · Cited by 21
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
“Lira-glutide inhibited NOX4 enzymatic activity, and this effect could be blocked by incubation with a protein kinase inhibitor or an adenylate cyclase inhibitor (62).”
Bai, F., Zhang, L., Zhang, W., Zheng, R., Eskew, J. R., Bennett, J., Wang, N.-P., Bose, H. S., & Zhao, Z. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172844 · Cited by 19
Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease
Ougaard, M. K., Sembach, F. E., Jensen, H. E., Pyke, C., Knudsen, L. B., & Kvist, P. H. (2020) · The Nephron journals/Nephron journals · doi:10.1159/000509418 · Cited by 20
Rodent models of diabetic kidney disease: human translatability and preclinical validity
Sembach, F. E., Østergaard, M. V., Vrang, N., Feldt‐Rasmussen, B., Fosgerau, K., Jelsing, J., & Fink, L. N. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.05.004 · Cited by 19
Memariani, Z., Hajimahmoodi, M., Minaee, B., Khodagholi, F., Yans, A., Rahimi, R., Amin, G., Moghaddam, G., Toliyat, T., & Sharifzadeh, M. S. (2017) · Europe PMC (PubMed Central) · Cited by 18
Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats
Abdellatif, R., Ahmed, A. F., & Heeba, G. H. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118592 · Cited by 21
Li, C., & Wang, Y. (2025) · Polymers · doi:10.3390/polym17060780 · Cited by 24
Fang, S., Cai, Y., Lyu, F., Zhang, H., Wu, C., Zeng, Y., Fan, C., Zou, S., Zhang, Y., Li, P., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9084567 · Cited by 19
Eraky, S. M., Ramadan, N. M., & El‐Magd, N. F. A. (2021) · Cell Biochemistry and Function · doi:10.1002/cbf.3678 · Cited by 18
Eissa, R. G., Eissa, N. G., Eissa, R. A., Diab, N. H., Abdelshafi, N. A., Shaheen, M. A., Elsabahy, M., & Hammad, S. K. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123549 · Cited by 17
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 16
Dipeptidyl peptidase-4 inhibition and renoprotection
Takagaki, Y., Koya, D., & Kanasaki, K. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000291 · Cited by 17
Luo, Y. L., Lü, K., Liu, G., Wang, J., Laurent, I., & Zhou, X. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0707-4 · Cited by 16
Oxidative stress–mediated photoactivation of carbazole inhibits human skin cell physiology
Srivastav, A. K., Dubey, D., Chopra, D., Singh, J., Negi, S., Mujtaba, S. F., Dwivedi, A., & Ray, R. S. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29360 · Cited by 16
Thong, K. Y., Walton, C., & Ryder, R. E. J. (2013) · Practical Diabetes · doi:10.1002/pdi.1748 · Cited by 16
Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
Kang, Y. M., & Jung, C. H. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.3.316 · Cited by 16
Protective Effects of Incretin Against Age-Related Diseases
Zhang, D., Ma, M., & Liu, Y. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191010145029 · Cited by 15
Huang, L., Ma, R., Lin, T., Chaudhari, S. K., Shotorbani, P. Y., Yang, L., & Wu, P. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219876531 · Cited by 15
Docherty, N. G., Murphy, M., Martin, F., Brennan, E. P., & Godson, C. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2014.078774 · Cited by 14
Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis
LIANG, R., Wang, M., Fu, C. L., Liang, H., Deng, H., Tan, Y. C. R. S., Xu, F. L., & Cai, M. (2020) · Endocrine Connections · doi:10.1530/ec-20-0294 · Cited by 14
Habib, H. A., Heeba, G. H., & Khalifa, M. M. A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119624 · Cited by 14
Potential cardioprotective action of GLP-1: from bench to bedside
Aronis, K. N., Tsoukas, M. A., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.009 · Cited by 14
Rodríguez, R., Escobedo, B., Lee, A. Y., Thorwald, M. A., Godoy-Lugo, J. A., Nakano, D., Nishiyama, A., Parkes, D. G., & Ortiz, R. M. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13206 · Cited by 14
Yao, M., Li, L., Ma, J., Xue, P., & Li, Y. (2019) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20198652 · Cited by 13
Incretin-based therapy: renal effects
Korbut, A. I., & Klimontov, V. V. (2016) · Diabetes Mellitus · doi:10.14341/dm7727 · Cited by 13
Igarashi, T., Niwano, S., Niwano, H., Yoshizawa, T., Nakamura, H. K., Fukaya, H., Fujiishi, T., Ishizue, N., Satoh, A., Kishihara, J., et al. (2018) · Heart and Vessels · doi:10.1007/s00380-018-1170-0 · Cited by 13
Azzi, D. V., Pereira, A. N. D. J., Silva, V. D. O., Foureaux, R. D. C., Lima, A. R. V., BARDUCCI, R. S., Albuquerque, A. S., dos Reis, G. L., de Oliveira, R. R., Andrade, E. F., et al. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00729-1 · Cited by 12
Chronic Kidney disease and stroke: A Bi-directional risk cascade and therapeutic update
Chavda, V. K., Chaurasia, B. K., Deora, H., & Umana, G. E. (2021) · Brain Disorders · doi:10.1016/j.dscb.2021.100017 · Cited by 12
Tsoukas, M. A., Farr, O. M., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.09.003 · Cited by 11
Concepts in Diabetic Nephropathy: From Pathophysiology to Treatment
Kinaan, M., Yau, H., Martinez, S., & Kar, P. M. (2017) · Journal of Renal and Hepatic Disorders · doi:10.15586/jrenhep.2017.17 · Cited by 10
Chen, C., Wu, V., Lin, C., Lin, C., Pan, C., Chen, H., Lin, Y., Huang, T., Chen, L., Wu, C., et al. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.06.023 · Cited by 11
Alicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00003-3 · Cited by 11
Cox, E. J., Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.80 · Cited by 10
Kheira, H. S., El‐Sayed, G., & El‐Adl, M. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150337 · Cited by 10
Forst, T. M., Michelson, G., Diessel, S., Jahnke, J., & Kapitza, C. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000776 · Cited by 10
Omachi, T., Ohara, M., Fujikawa, T., Kohata, Y., Sugita, H., Irie, S., Terasaki, M., Mori, Y., Fukui, T., & Yamagishi, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01493-3 · Cited by 11
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 14
Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline
Yi, B., Su, K., Cai, Y., Chen, X., Bao, Y., & Wen, Z. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176905 · Cited by 10
Morales, J., & Palmer, B. F. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2316572 · Cited by 9
Bodini, S., Pieralice, S., D’Onofrio, L., Mignogna, C., Coraggio, L., Amendolara, R., Risi, R., Salducci, M., Buzzetti, R., & Maddaloni, E. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.04.009 · Cited by 10
Colin, I. M., Colin, H., Dufour, I., Gielen, C.-E., Many, M., Saey, J.-P., Knoops, B., & Gérard, A.-C. (2016) · Physiological Reports · doi:10.14814/phy2.12886 · Cited by 9
Chan, D., Lin, Y.-C., Tzeng, H.-P., Yang, R., Chiang, M., & Liu, S. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102479 · Cited by 9
Liljedahl, L., Norlin, J., McGuire, J. N., & James, P. (2017) · Physiological Reports · doi:10.14814/phy2.13187 · Cited by 7
Incretins in the Therapy of Diabetic Kidney Disease
Przezak, A., Bielka, W., & Pawlik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212312 · Cited by 7
Ninčević, V., Zjalić, M., Kolarić, T. O., Smolić, M., Kizivat, T., Kuna, L., Včev, A., Tabll, A. A., & Bilić-Čurčić, I. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44030072 · Cited by 7
Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation
Wasim, R., Ansari, T. M., Siddiqui, M. H., Ahsan, F., Shamim, A., Singh, A. N., Shariq, M., Anwar, A., Siddiqui, A. R., & Parveen, S. (2023) · Hormone and Metabolic Research · doi:10.1055/a-1971-6965 · Cited by 7
Ge, G., Dou, H., Yang, S.-S., Ma, J., Cheng, W., Qiao, Z., Hou, Y., & Fang, W. (2015) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(14)60191-7 · Cited by 7
The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 7
Rodent models to study type 1 and type 2 diabetes induced human diabetic nephropathy
Talukdar, A., & Basumatary, M. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08621-z · Cited by 8
Bidirectional relation between dipeptidyl peptidase 4 and angiotensin II type I receptor signaling
Martins, F. L., Ribeiro-Silva, J. C., Nistala, R., & Girardi, A. C. C. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00734.2023 · Cited by 6
Renal Disease in Diabetes Mellitus: Recent Studies and Potential Therapies
Iqbal, S. (2013) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s9-006 · Cited by 6
Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus
Vikulova, O. K., Zuraeva, Z. T., Michaleva, O. V., Nikankina, L. V., Шамхалова, М. Ш., Shestakova, M. V., & Dedov, I. I. (2018) · Terapevticheskii arkhiv · doi:10.26442/terarkh201890659-64 · Cited by 6
Kumar, G., Saini, M., & Kundu, S. (2021) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0732 · Cited by 6
Aono, M., & Sato, Y. (2016) · Renal Replacement Therapy · doi:10.1186/s41100-016-0058-7 · Cited by 6
Impact of CVOTs in primary and secondary prevention of kidney disease
Cosmo, S. D., Viazzi, F. C., Piscitelli, P. A., Leoncini, G., Mirijello, A., Bonino, B., & Pontremoli, R. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107907 · Cited by 6
Meng, Y., Wang, Y., Fu, W., Zhang, M., Huang, J., Wu, H., & Sun, L. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02575-6 · Cited by 6
Peng, H., Ren, J., Zhao, Y., Fang, X., Wang, X., Liu, C., & Wan, Z. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112235 · Cited by 7
Zhou, L., Liu, D., Wang, Z., Dong, H., Xu, X., & Zhou, S. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/8929620 · Cited by 5
Effektive antidiabetische Therapie zur Vorbeugung einer diabetischen Nephropathie
Muller, N., Busch, M., Gerdes, C., & Wolf, G. (2023) · Nephrologie aktuell · doi:10.1055/a-2055-3322 · Cited by 5
Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side
Abdelrahman, A. M., Awad, A. S., Hasan, I., & Abdel‐Rahman, E. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247732 · Cited by 4
Li, W., Liang, X., Sun, N., & Zhang, D. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01948-7 · Cited by 5
Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management
Lian, K., Zhang, K., Kan, C., Hou, N., Han, F., Sun, X., Qiu, H., & Guo, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122801 · Cited by 5
Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy
Zhang, Q., Yang, M., Xiao, Y., Han, Y., Yang, S., & Sun, L. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191108160643 · Cited by 4
Block, T. J., & Cooper, M. E. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104178 · Cited by 4
Jang, C.-W., Yu, T. Y., Jeong, J. W., Ha, S. E., Singh, R., Lee, M. Y., & Ro, S. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14030280 · Cited by 3
Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome
Ge, M., Molina, J., Tamayo, I. M., Zhang, G., Kim, J., Njeim, R., Fontanesi, F., Pieper, M. P., Merscher, S., Sharma, K., et al. (2024) · Kidney360 · doi:10.34067/kid.0000000000000472 · Cited by 5
Albanna, A., Ibrahim, D. A., Shamsher, A., Al-Shawia, M. A. A., & Halboup, A. M. (2025) · Journal of Experimental Pharmacology · doi:10.2147/jep.s522053 · Cited by 3
A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats
Seikrit, C., Lausberg, E., Buhl, E. M., Gáspár, R., Tábi, T., Heffer, M., Ducza, E., Sztojkov‐Ivanov, A., Seres, A. B., Szűcs, K. F., et al. (2021) · Cellular Physiology and Biochemistry · doi:10.33594/000000476 · Cited by 3
He, Y., Xu, R., Ma, X., Zhou, J., & Qiu, L. (2024) · Translational Pediatrics · doi:10.21037/tp-23-518 · Cited by 3
Therapeutic effect of liraglutide on expression of CTGF and BMP‐7 in induced diabetic nephropathy
Ramzy, M. M., Abdalla, A. M., Zenhom, N. M., Okasha, A., Abdelkafy, A. E., & Saleh, R. K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29015 · Cited by 4
Metadata
- Authors
- Hendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R.
- Affiliations
- Kyushu University (JP)
- Corresponding author
- Inoguchi, Toyoshi
- ORCID
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 61
- Issue
- 10
- Pages
- 1422-1434
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W1983883248
- Cited by
- 232
- References
- 43
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 20 · 2023: 16 · 2022: 8 · 2021: 17 · 2020: 21 · 2019: 21 · 2018: 18 · 2017: 15 · 2016: 16 · 2015: 19 · 2014: 14 · 2013: 18 · 2012: 4
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Universitas Islam Negeri Syarif Hidayatullah Institutional Repository (Universitas Islam Negeri Syarif Hidayatullah Jakarta) (submittedVersion, cc-by-nc)
- Funders
- Japan Society for the Promotion of Science (23390247)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- liraglutide, GLP-1 analogues, diabetic nephropathy, oxidative stress, albuminuria, protein kinase A, NADPH oxidase, type 1 diabetes, streptozotocin-induced diabetes, renal mesangial cells, superoxide production, TGF-beta, fibronectin, Epac2, renal fibrosis
- MeSH terms
- Liraglutide, Adenine, Albuminuria, Animals, Cells, Cultured, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Humans, Isoquinolines, Kidney, Male, Multienzyme Complexes, NADH, NADPH Oxidoreductases, Streptozocin, Sulfonamides, Rats, Wistar, Cyclic AMP-Dependent Protein Kinases, Oxidative Stress, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review